Esther Kim
Esther Kim has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Tushar Garg
Department of Radiology and Radiological Sciences, Division of Neuroradiology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
4 shared publications - Ahmed M. Gabr
Department of Interventional Radiology, OHSU and Tanta University, Portland, USA
2 shared publications - Ciléin Kearns
Radiology Department, Wellington Regional Hospital, Wellington, New Zealand
2 shared publications - David Hilton Ballard
Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
2 shared publications - Jolie Jean
From the Department of Radiology, Max Rady College of Medicine, University of Manitoba, 820 Sherbrooke St, GA-216, Winnipeg, MB, Canada R3A 1R9 (E.K.); Department of Surgery, Stamford Health/Columbia University College of Physicians and Surgeons, Stamford, Conn (J.J.); Medical Research Institute of New Zealand, Wellington, New Zealand, and Artibiotics, Wellington, New Zealand (C.K.); and Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo (D.H.B.).
2 shared publications - Ajay Malhotra
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT 06520, USA
1 shared publication
Latest Publications
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (3) , e240239
Multisystem Imaging Manifestations of Fibromuscular Dysplasia
Evaluation for fibromuscular dysplasia and its potentially devastating complications is essential in at-risk patient populations, and radiologists play an important role in timely identification of associated morbidities and contribute to its early diagnosis and treatment.
- 1 March 2026
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 46 (3) , e240239
Multisystem Imaging Manifestations of Fibromuscular Dysplasia
Evaluation for fibromuscular dysplasia and its potentially devastating complications is essential in at-risk patient populations, and radiologists play an important role in timely identification of associated morbidities and contribute to its early diagnosis and treatment.
- 1 January 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (1) , e220183
Radiology and Advocacy: How Trainees Can Make a Difference
- 1 January 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (1) , e220183
Radiology and Advocacy: How Trainees Can Make a Difference
- 1 May 2022
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 42 (3) , E88-E89
Multiple Systemic Arterial Aneurysms in Kawasaki Disease
- 1 May 2022
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 42 (3) , E88-E89
Multiple Systemic Arterial Aneurysms in Kawasaki Disease
- 1 October 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (6) , 1570-1571
Perivenous Hepatic Iron Deposition in Alcoholic Cirrhosis
- 1 October 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (6) , 1570-1571
Perivenous Hepatic Iron Deposition in Alcoholic Cirrhosis
- 1 September 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (5) , E142-E144
Addressing Global Radiology Disparities: Increasing Access to Interventional Radiology Education
- 1 September 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (5) , E142-E144
Addressing Global Radiology Disparities: Increasing Access to Interventional Radiology Education
- 1 March 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (2) , E60
RG TEAM Highlights Importance of Trainee Involvement in RadioGraphics
- 1 March 2021
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 41 (2) , E60
RG TEAM Highlights Importance of Trainee Involvement in RadioGraphics
- Open Access
- 20 May 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (7) , 1302-1305
Durable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
There are rare patients with metastatic colon cancer who experience dramatic and durable responses. Primary tumor location is a prognostic and potentially predictive factor and should be taken into consideration when deciding on the optimal first‐line therapy to be used in combination with chemotherapy.
- 20 May 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (7) , 1302-1305
Open AccessDurable complete response in a patient with metastatic left‐sided colon cancer treated with 5‐fluorouracil, folinic acid, and irinotecan (FOLFIRI) and panitumumab: A case report
There are rare patients with metastatic colon cancer who experience dramatic and durable responses. Primary tumor location is a prognostic and potentially predictive factor and should be taken into consideration when deciding on the optimal first‐line therapy to be used in combination with chemotherapy.
- 1 September 2015
- Published by Springer Nature in Drugs
- Vol. 75 (13) , 1547-1557
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Empagliflozin/linagliptin (Glyxambi®) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empagliflozin and linagliptin is appropriate. This article reviews the clinical efficacy and tolerability of oral empagliflozin/linagliptin in patients with T2D and summarizes the pharmacological properties of the agents. Results of two randomized controlled trials of 52 weeks’ duration in adults with T2D demonstrated that empagliflozin/linagliptin improved glycaemic control significantly more than linagliptin when administered as initial therapy (whereas results vs. empagliflozin were mixed in this setting) and significantly more than linagliptin or empagliflozin when administered as an add-on therapy to metformin. In addition to glycaemic control, empagliflozin/linagliptin provided significant weight loss compared with linagliptin in both trials. Empagliflozin/linagliptin was generally well tolerated in patients with T2D, with a low risk of hypoglycaemia and no reports of exacerbations of, or hospitalizations for, heart failure during the trials. As the first SGLT2 inhibitor/DPP-4 inhibitor fixed-dose combination available, empagliflozin/linagliptin is a useful new option for patients with T2D.
- 1 September 2015
- Published by Springer Nature in Drugs
- Vol. 75 (13) , 1547-1557
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Empagliflozin/linagliptin (Glyxambi®) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empagliflozin and linagliptin is appropriate. This article reviews the clinical efficacy and tolerability of oral empagliflozin/linagliptin in patients with T2D and summarizes the pharmacological properties of the agents. Results of two randomized controlled trials of 52 weeks’ duration in adults with T2D demonstrated that empagliflozin/linagliptin improved glycaemic control significantly more than linagliptin when administered as initial therapy (whereas results vs. empagliflozin were mixed in this setting) and significantly more than linagliptin or empagliflozin when administered as an add-on therapy to metformin. In addition to glycaemic control, empagliflozin/linagliptin provided significant weight loss compared with linagliptin in both trials. Empagliflozin/linagliptin was generally well tolerated in patients with T2D, with a low risk of hypoglycaemia and no reports of exacerbations of, or hospitalizations for, heart failure during the trials. As the first SGLT2 inhibitor/DPP-4 inhibitor fixed-dose combination available, empagliflozin/linagliptin is a useful new option for patients with T2D.